Testing a Causal Model of Cognitive Control Deficits in Posttraumatic Stress Disorder (PTSD)
NCT ID: NCT06016673
Last Updated: 2024-04-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2023-09-13
2024-02-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Brain Structure and Function Before and After Treatment for Post-Traumatic Stress Disorder
NCT00069225
Pathophysiological Understanding and Treatment of PTSD: an rTMS Approach
NCT03840369
Brain Response to Treatment for Pediatric PTSD
NCT01806701
Brain Imaging of Psychotherapy for Posttraumatic Stress Disorder (PTSD)
NCT01507948
Brain Indices of Risk for Posttraumatic Stress Disorder (PTSD) After Mild Traumatic Brain Injury (mTBI)
NCT01625962
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intermittent theta burst stimulation to right dorsolateral prefrontal cortex
Participants will receive intermittent theta burst stimulation (iTBS) to the experimental target area, the right dorsolateral prefrontal cortex (rDLPFC)
Transcranial Magnetic Stimulation (TMS)
Participants will receive intermittent theta burst stimulation (iTBS) to two brain areas, the right dorsolateral prefrontal cortex (rDLPFC) and the vertex.
Intermittent theta burst stimulation to vertex of the skull
Participants will receive intermittent theta burst stimulation (iTBS) to the active comparator area, the vertex of the skull
Transcranial Magnetic Stimulation (TMS)
Participants will receive intermittent theta burst stimulation (iTBS) to two brain areas, the right dorsolateral prefrontal cortex (rDLPFC) and the vertex.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transcranial Magnetic Stimulation (TMS)
Participants will receive intermittent theta burst stimulation (iTBS) to two brain areas, the right dorsolateral prefrontal cortex (rDLPFC) and the vertex.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Endorse lifetime exposure to at least one Criterion A traumatic event
* Report clinically significant posttraumatic stress disorder (PTSD) symptoms (score of ≥ 33 on the PTSD Checklist for DSM-5 \[PCL-5\]).
Exclusion Criteria
* Report an unstable medical condition or any current medical condition that precludes safe participation in the trial (e.g., unstable metabolic abnormality, unstable angina, etc.)
* Report any history or diagnosis of dementia or other cognitive disorder, which may interfere with engagement
* Report any history or diagnosis of Severe Traumatic Brain Injury
* Report any history or diagnosis of Schizophrenia, Schizoaffective Disorder, Delusional Disorder or other psychotic illness, which precludes safe participation in the trial
* Report a primary obsessive-compulsive disorder (OCD) diagnosis
* Report an active substance use disorder (within last 3 months) or any current substance use that precludes safe participation in the trial
* Report suicide risk that precludes safe participation in the trial, defined as clinical impression that the participant is at significant risk for suicide (i.e., greater than moderate level of suicide risk, in accordance with the Joiner et al. (1999) suicide risk framework)
* Report an inability to stop taking any medication that significantly lowers the seizure threshold (e.g., tricyclic antidepressants, clozapine, etc.)
* Report a current, planned, or suspected pregnancy
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Florida State University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Carter Bedford
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Norman B Schmidt, PhD
Role: PRINCIPAL_INVESTIGATOR
Distinguished Research Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Florida State University College of Medicine
Tallahassee, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00003574
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.